Approved Drugs (Cancer Types)

. Trastuzumab deruxtecan (DS-8201): HER2 breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC)

. Rituximab trastuzumab (SHR-A1811): HER2 non-small cell lung cancer, biliary tract cancer (planned breakthrough therapy in 2025)

Clinical Trial Drugs (Cancer Types)

. BB-1701 (Bellicica): HER2 breast cancer/NSCLC (Phase III)

. SHR-A2009 (Hengrui): HER3/HER2 dual targeting, EGFR-mutant lung cancer (Phase II)

. RC48 (RemeGen): HER2 gastric cancer, urothelial carcinoma (Phase III)

Approved Drugs (Cancer Types)

. Enfortumab Vedotin (Padcev): Urothelial carcinoma (approved worldwide, used for patients with locally advanced or metastatic urothelial carcinoma)

Clinical Trial Drugs (Cancer Types)

. HS-20093 (Hansoh Pharma): Combined Immunotherapy for Osteosarcoma (Phase III)

Approved Drugs (Cancer Types)

. Sacituzumab Govitecan (Trodelvy): Triple-negative breast cancer (TNBC), urothelial carcinoma (marketed globally)

Clinical Trial Drugs (Cancer Types)

. ESG401: PD-L1 Negative TNBC (Breakthrough Therapy)

. IBI130 (Innovent Biologics): Solid Tumors (Phase I/II)

. SHR-A1921 (Hengrui): Platinum-Resistant Ovarian Cancer (DCR 100%)

Approved Drugs (Cancer Types)

. Tivdak (tisotumab vedotin): Cervical cancer (the world's first TF-ADC, for patients with recurrent or metastatic cervical cancer)

Clinical Trial Drugs (Cancer Types)

. XNW28012 (Xinnuo Wei): Pancreatic cancer (Stage III, breakthrough therapy)

Approved Drugs (Cancer Types)

. Somituximab (Elahere): platinum-resistant ovarian cancer (introduced by Huadong Medicine for patients with high FRα expression)

Clinical Trial Drugs (Cancer Types)

. HDM2027 (Huadong Medicine): Ovarian Cancer (Stage I)